Compare EDUC & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDUC | IMNN |
|---|---|---|
| Founded | 1965 | 1982 |
| Country | United States | United States |
| Employees | 64 | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3M | 10.8M |
| IPO Year | 1995 | 2000 |
| Metric | EDUC | IMNN |
|---|---|---|
| Price | $1.44 | $2.26 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 52.7K | 44.5K |
| Earning Date | 05-19-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 142.86 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $22,913,600.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.37 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.01 | $0.48 |
| 52 Week High | $1.84 | $9.32 |
| Indicator | EDUC | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 58.13 | 28.45 |
| Support Level | $1.25 | N/A |
| Resistance Level | $1.50 | $3.24 |
| Average True Range (ATR) | 0.07 | 0.19 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 69.00 | 13.82 |
Educational Development Corp distributes books and educational products and publications through its PaperPie and EDC Publishing divisions to individual consumers, book, toy and gift stores, libraries and home educators located throughout the United States. The company is the owner and exclusive publisher of Kane Miller children's books; Learning Wrap-Ups, maker of educational manipulatives; and SmartLab Toys, maker of STEAM-based toys and games. It also the exclusive United States Multi-Level Marketing (MLM) distributor of Usborne Publishing Limited (Usborne) children's books. It sell children's books, educational toys and games and other related products. It has two reportable segments: PaperPie and Publishing of which majority of revenue comes from Paperpie.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.